1Snapir A,Posti J,Kentala E,et al.Effects of low and high plasma concentrations of dexmedetomidine on myocardial perfusion and cardiac function in healthy male subjects.Aneethesiology,2006,105(5):902.
3Walker SM,Howard RF,Keay KA,et al.Developmental age influences the effect of epidural dexmedetomidine on inflammatory hyperalgesia in the rat pups.Anesthesiology,2005,102(3):1126.
1Kamibayashi T, Maze M. Clinical uses of ctz-adrenergic agonists, Anesthesiology, 2000, 93:1345-1349.
2Ilfeld BM, Moray TE, Thannikary LJ, at al. Clonidine added to a continuous interscalene ropivacaine perineural infusion to improve postoperative analgesia: a randomized, doubleblind,controlled study. Anesth Analg, 2005, 100:1172-1178.
3Hall JE, Uhrich TD, Barney JA, et al. Sedative, amnestic and analgesic properties of small dose dexmedetomidine infusions.Anesth Analg,2000,90:699-705.
4Ebert TJ, Hall JE, Barney JA, et al. The effects of increase plasma concentration of dexmedetomidine in humans. Anesthesiology, 2000, 93: 382-394.
5Correa Sales C, Rabin BC, Maze M. A hypnotic response to dexmedetomidine, an α2 agonist, is mediated in the locus eoer uleus in rats. Anesthesiology, 1992, 76: 948-952.
6Hayashi Y, Rabin BC, Guo TZ, et al. Role of pertussis toxinsensitive G-proteins in the analgesic and anesthetic action of α2-adrenergic agonlsts in the rat, Anesthesiology, 1995, 83: 816-822.
7Arain SR, Ebert TJ. The efficacy, side effects, and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative sedation. Anesth Analg, 2002, 95: 461-466.
8Khan ZP, Munday IT, Jones RM, et al, Effects of dexmedetomidine on isoflurane requirements in healthy volunteers, 1:Pharmacodynamic and pharmacokinetic interactions. Br J Anaesth, 1999, 83: 372-380.
9Venn RM, Bradshaw CJ, Spencer R, et al. Preliminary UK experience of dexmedetomine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia, 1999, 54:1136-1142.
10Fragen RJ, Fitzgerald PC. Effect of dexmedetomidine on the minimum alveolar concentration (MAC) of sevoflurane in adults age 55 to 70 years. J ClinAnesth, 1999, 11: 466-470.
